Author name: admingav

EVER Symposium: Defusing the ticking timebomb of high myopia

If current trends continue, one out of every two people on the planet will be myopic by the year 2050. Even more worryingly, a significant proportion of these will be highly myopic with all the associated problems that entails in terms of ocular morbidity, disease and vision loss, according to a number of speakers at […]

EVER Symposium: Defusing the ticking timebomb of high myopia Read More »

Charting EURETINA’s future: collaboration, standards, and cutting-edge research

Prof. Ramin Tadayoni, the incoming President of EURETINA, discusses the challenges and opportunities facing the Society over the next few years To what do you attribute the phenomenal growth of EURETINA in recent years? Ramin Tadayoni: EURETINA is still quite a young Society and a lot has been achieved in a short space of time.

Charting EURETINA’s future: collaboration, standards, and cutting-edge research Read More »

AI, clinical trials & diabetic eye disease all on the menu at Imaging session

Speakers at the Euretina session on imaging reviewed applications for a variety of retinal diseases. Leading off the programme, Dr Pearse Keane (UK) discussed the application of artificial intelligence (AI) for analysing OCT scans and predicted that the biggest impact of the application of AI in AMD in the near future would be to enable

AI, clinical trials & diabetic eye disease all on the menu at Imaging session Read More »

Euretina reiterates support at Ukraine Symposium

Presentations by Ukrainian retina specialists speaking at the Ukraine Support Symposium on Friday afternoon described the devastating eye injuries suffered by Ukrainian soldiers and civilians in the ongoing war with Russia and described the complex surgical approaches needed to manage these traumatic cases.   Opening the session, Dr Camiel Boon (Netherlands) observed that while retina

Euretina reiterates support at Ukraine Symposium Read More »

Opening Ceremony kicks off 23rd Euretina Congress

There are 8,000 registered attendees for the 23rd Euretina Congress in Amsterdam, also marking a return to the level of in-person attendance last seen in 2019.  At the beginning of the opening ceremony on Thursday afternoon, Euretina President Dr Alistair Laidlaw extended a very warm welcome to those who gathered in the Grand Auditorium. “It’s

Opening Ceremony kicks off 23rd Euretina Congress Read More »

Vitreoretinal Surgery: Seeking the ground truth; evidence-based medicine approaches in retinal detachment and macular holes

A huge number of Euretina Congress delegates filled the Grand Auditorium to hear speakers at the first Euretina Session of the meeting. The session focused on vitreoretinal surgery and specifically centred on evidence-based medicine approaches in cases of retinal detachment and macular holes.   The primary aim of the session was not to share new

Vitreoretinal Surgery: Seeking the ground truth; evidence-based medicine approaches in retinal detachment and macular holes Read More »

136th Retinal Detachment Teaching Course: an enduring institution rolls on

Mix of formats engage attendees and enhance learning in the 136th Retinal Detachment Teaching Course EURETINA delegates who attended the Retinal Detachment Teaching Course represent participants in the 136th iteration of this programme that was first organised by Professor Ingrid Kreissig in 1991. The course at the EURETINA Congress is just one of several that

136th Retinal Detachment Teaching Course: an enduring institution rolls on Read More »

Investment firm representatives at EIS provide positive outlook and constructive advice for innovators

Retina specialists who have innovative ideas for new therapies and devices heard encouraging words from panellists participating in the “Investing in Retina” session at the EURETINA Innovation Spotlight. Representing European- and US-based venture capital firms that provide financing for research and development of entities that may be just a new idea emanating from an “AHA”

Investment firm representatives at EIS provide positive outlook and constructive advice for innovators Read More »

EURETINA Innovation Spotlight (EIS) kicks off with a focus on intensive innovation in treatment modalities

Evidence of burgeoning research to develop new medical therapeutics for retinal diseases was strong at the EURETINA Innovation Spotlight (EIS) where two 75-minute sessions were devoted to innovation in medical therapy. During the dual sessions, speakers representing 13 companies took to the podium to showcase their company’s pipeline, and panel discussions at the end of

EURETINA Innovation Spotlight (EIS) kicks off with a focus on intensive innovation in treatment modalities Read More »